Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

7.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.6K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.9K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.9K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

6.7K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SiCLIP: An explainable multimodal framework for silicosis diagnosis.

Artificial intelligence in medicine·2026
Same author

TRIM21 facilitates inflammasome assembly and contributes to autoinflammatory disease.

Nature communications·2026
Same author

Biological Indicators and Process Challenge Devices for Nitrogen Dioxide Sterilization.

Biomedical instrumentation & technology·2026
Same author

Healthcare system readiness to manage viral hepatitis in Viet Nam and the Philippines: results of a brief health facility assessment.

BMC health services research·2026
Same author

Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data.

JTO clinical and research reports·2026
Same author

PML Is Limiting NLRP3 Inflammasome Activity in Human Endothelial Cells.

Cells·2025

Related Experiment Video

Updated: Mar 22, 2026

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.8K

20-HETE contributes to ischemia-induced angiogenesis.

Li Chen1, Gregory Joseph2, Frank F Zhang2

  • 1Department of Pharmacology, New York Medical College, Valhalla, NY 10595, USA; State Key Lab of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China.

Vascular Pharmacology
|April 17, 2016
PubMed
Summary

20-hydroxyeicosatetraenoic acid (20-HETE) promotes recovery from peripheral ischemia by enhancing blood flow and new blood vessel formation. Inhibiting 20-HETE synthesis or its action impairs this crucial angiogenesis process.

More Related Videos

In Vitro Model of Coronary Angiogenesis
08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

8.6K
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

9.3K

Related Experiment Videos

Last Updated: Mar 22, 2026

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.8K
In Vitro Model of Coronary Angiogenesis
08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

8.6K
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

9.3K

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Physiology

Background:

  • Angiogenesis is vital for peripheral ischemia recovery.
  • The role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia-induced angiogenesis requires elucidation.

Purpose of the Study:

  • To investigate the contribution of 20-HETE to ischemia-induced angiogenesis.
  • To explore the molecular and cellular mechanisms underlying 20-HETE's role in this process.

Main Methods:

  • Mouse hindlimb ischemia model.
  • Laser Doppler Perfusion Imaging for blood flow assessment.
  • CD31 and tomato lectin staining for microvessel density.
  • LC/MS/MS for 20-HETE quantification.
  • Immunofluorescence for CYP4A12, HIF-1α, VEGF, VEGFR2, and ERK1/2 expression analysis.

Main Results:

  • Inhibitors of 20-HETE synthesis (DDMS) and action (6,15-20-HEDGE) reduced blood flow recovery and microvessel formation.
  • Ischemia increased 20-HETE production and CYP4A12 expression in muscles, with CYP4A12 localized to endothelial cells.
  • Ischemia upregulated HIF-1α, VEGF, and VEGFR2, effects abolished by DDMS and 6,15-20-HEDGE.
  • ERK1/2 activation was identified as a downstream mediator of 20-HETE in ischemic angiogenesis.

Conclusions:

  • 20-HETE is a critical mediator of ischemia-induced angiogenesis.
  • 20-HETE regulates key angiogenic pathways including HIF-1α and VEGF signaling.
  • Targeting 20-HETE may offer therapeutic strategies for peripheral ischemia.